{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:03:32Z","timestamp":1789578212854,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006737","name":"National Center of Excellence for Clinical Trial and Research","doi-asserted-by":"publisher","award":["111-CTC0008"],"award-info":[{"award-number":["111-CTC0008"]}],"id":[{"id":"10.13039\/501100006737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006737","name":"National Center of Excellence for Clinical Trial and Research","doi-asserted-by":"publisher","award":["112-CTC0020"],"award-info":[{"award-number":["112-CTC0020"]}],"id":[{"id":"10.13039\/501100006737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006737","name":"National Center of Excellence for Clinical Trial and Research","doi-asserted-by":"publisher","award":["113-CTC0017"],"award-info":[{"award-number":["113-CTC0017"]}],"id":[{"id":"10.13039\/501100006737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 111-2314-B-002-296"],"award-info":[{"award-number":["NSTC 111-2314-B-002-296"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-002-317"],"award-info":[{"award-number":["NSTC 113-2314-B-002-317"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["114-O0032"],"award-info":[{"award-number":["114-O0032"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["114-N0027"],"award-info":[{"award-number":["114-N0027"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["112-BIH032"],"award-info":[{"award-number":["112-BIH032"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Graves\u2019 orbitopathy (GO) is a prevalent manifestation of Graves\u2019 disease (GD), characterized by proptosis, eyelid retraction, soft tissue swelling, diplopia, and potential visual acuity impairment. Furthermore, even mild GO can significantly impact mental health and overall quality of life for patients with GD. Despite its severity, available medical treatments for mild GO are limited. Recent basic studies on orbital fibroblasts suggest hydroxychloroquine (HCQ) as a promising therapeutic agent for GO patients. This randomized controlled trial (RCT) was designed to assess the efficacy of HCQ in treating mild GO.\u00a0<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multi-center open-label RCT will be conducted in Taiwan with a total of 108 participants randomized into HCQ and control groups at 2:1 allocation ratio. The primary endpoint of this study is a composite outcome of ophthalmic parameters including eyelid aperture, soft tissue involvement, and exophthalmos. Secondary endpoints comprise changes in quality of life (GO-QoL), orbital volumetry via computed tomography (CT), diplopia scores, clinical activity scores (CAS), visual acuity, and thyroid autoantibodies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This RCT will elucidate the clinical benefits of oral HCQ in patients with mild GO, assessing ophthalmic outcomes, quality of life, disease activity, and thyroid autoantibodies. In addition, data obtained from orbital CT measurements will provide valuable insights into subtle changes in orbital fat and extra-ocular muscle volumes, potentially offering an objective tool for monitoring GO progression.\n<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration\u00a0{2a, 2b}<\/jats:title>\n            <jats:p>ClinicalTrials.gov NCT05126147.\u00a0Registered on November 2021.\u00a0<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05126147\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT05126147<\/jats:ext-link>. All items from the World Health Organization (WHO) Trial Registration Data Set are addressed within the relevant sections of this protocol.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09002-6","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T22:38:23Z","timestamp":1754347103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A randomized controlled trial on the effect of hydroxychloroquine in mild Graves\u2019 orbitopathy (GO-HCQ): study protocol"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-7420","authenticated-orcid":false,"given":"Chia-Hung","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyang-Rong","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"16","key":"9002_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L. Graves\u2019 disease. N Engl J Med. 2016;375(16):1552\u201365.","journal-title":"N Engl J Med"},{"issue":"6","key":"9002_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1210\/clinem\/dgaa161","volume":"105","author":"Y Guo","year":"2020","unstructured":"Guo Y, Li H, Chen X, Yang H, Guan H, He X, et al. Novel roles of chloroquine and hydroxychloroquine in Graves\u2019 orbitopathy therapy by targeting orbital fibroblasts. J Clin Endocrinol Metab. 2020;105(6):1906\u201317.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9002_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","volume":"42","author":"P Perros","year":"1995","unstructured":"Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42(1):45\u201350.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"20","key":"9002_CR4","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med. 2011;364(20):1920\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"9002_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.scitotenv.2006.03.004","volume":"367","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Lai JS, Wu CC, Lin TS. Serum selenium in adult Taiwanese. Sci Total Environ. 2006;367(1):448\u201350.","journal-title":"Sci Total Environ"},{"issue":"5","key":"9002_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ICU.0000000000000402","volume":"28","author":"D Strianese","year":"2017","unstructured":"Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol. 2017;28(5):505\u201313.","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"9002_CR7","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9002_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, Pitz S, Ponto K, Diana T, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"9002_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352.","journal-title":"N Engl J Med"},{"key":"9002_CR10","unstructured":"Stokkermans TJ, Goyal A, Bansal P, Trichonas G. Chloroquine and hydroxychloroquine toxicity. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2020, StatPearls Publishing LLC. 2020."},{"issue":"12","key":"9002_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1439\u201370.","journal-title":"Thyroid"},{"issue":"10","key":"9002_CR12","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284\u201390.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"9002_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"9002_CR14","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1167\/iovs.07-1030","volume":"49","author":"NI Regensburg","year":"2008","unstructured":"Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, et al. A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci. 2008;49(5):1758\u201362.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"9002_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16(2):391\u2013407.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"9002_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"9002_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jfma.2013.12.002","volume":"114","author":"IC Lin","year":"2015","unstructured":"Lin IC, Lee CC, Liao SL. Assessing quality of life in Taiwanese patients with Graves\u2019 ophthalmopathy. J Formos Med Assoc. 2015;114(11):1047\u201354.","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"9002_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/eye.2016.298","volume":"31","author":"IH Yusuf","year":"2017","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828\u201345.","journal-title":"Eye (Lond)"},{"issue":"6","key":"9002_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.1997.7.885","volume":"7","author":"MN Gerding","year":"1997","unstructured":"Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7(6):885\u20139.","journal-title":"Thyroid"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09002-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:55:56Z","timestamp":1757350556000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09002-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9002"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09002-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"12 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed informed consent before enrollment, and the institutional review board  of National Taiwan University Hospital reviewed and approved the study protocol  (202101055MINB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A copy of the participant informed consent form (in tTraditional Chinese) is provided as a  supplementary file.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"272"}}